Key result
Propranolol is linked to a 0.19 increase in adolescent BMI z-score, whereas lisinopril lowers it.
Why the study?
Antihypertensive class medications are prescribed long-term for adolescents, including for non-hypertension indications, but evidence regarding their effects on weight is limited.
Do antihypertensive class medications alter BMI z-score in adolescents?
Cohort (n=23,853)
Yes
Do antihypertensive class medications alter BMI z-score in adolescents?
Most commonly prescribed antihypertensive medications do not cause significant weight gain in adolescents, though propranolol is associated with a slight increase and lisinopril with a slight decrease in BMI z-score.
Answers are grounded in this paper and cite their sources.
May warrant BMI monitoring with propranolol in adolescents; leaves open causality and effects beyond this cohort.
BACKGROUND: Antihypertensive class medications are prescribed long-term for adolescents, including for conditions other than hypertension. Evidence on weight effects is limited. OBJECTIVE: To assess the weight effects of commonly prescribed antihypertensive class medications among adolescents, regardless of clinical indication for use. METHODS: This retrospective study was conducted using electronic health record (EHR) data from a multi-site US research network. The study cohort included adolescents aged 13.0-19.5 years with ≥ 1 antihypertensive class medication order during 2010-2019. Weight and height documented in the EHR were used to calculate BMI z-scores. Inverse probability weighting with marginal structural models was used to account for selection factors and covariates. RESULTS: Overall, 23 853 adolescents were prescribed an antihypertensive class medication, including clonidine (prescribed to n = 7491), guanfacine (n = 6411), lisinopril (n = 3584), propranolol (n = 3015), spironolactone (n = 1926), and atenolol (n = 1426). At baseline, 13% had a hypertension diagnosis. At 12 months after medication initiation, the estimated population-level BMI z-score was significantly increased for propranolol (BMI z-score 0.19 [95% CI 0.09, 0.29]) and significantly decreased for lisinopril (-0.06 [95% CI -0.10, -0.01]); clonidine, guanfacine, spironolactone, and atenolol were not associated with a significant change in BMI z-score. CONCLUSIONS: Most antihypertensive class medications were not associated with statistically significant weight gain when prescribed to adolescents.
No takes yet. Share an insight, caveat, or question.
Daley et al. (2026) conducted a cohort in Adolescents prescribed antihypertensive class medications (n=23,853). Antihypertensive class medications (clonidine, guanfacine, lisinopril, propranolol, spironolactone, atenolol) was evaluated on BMI z-score at 12 months after medication initiation (BMI z-score change 0.19 (propranolol), -0.06 (lisinopril), 95% CI 0.09 to 0.29 (propranolol), -0.10 to -0.01 (lisinopril)). Propranolol increased BMI z-score and lisinopril decreased it at 12 months in adolescents, with no significant change for others.
Synapse has enriched 10 related papers. Consider them for comparative context: